ArticleBreast cancer research and treatment2022

Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer.

Ridho Assidicky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.